Express Scripts CEO Sees Transparency Law Consequences
This article was originally published in The Pink Sheet Daily
PBMs are able to secure better prices from manufacturers without transparency, Paz says.
You may also be interested in...
PCMA To Continue To Fight D.C. PBM Transparency Law
D.C. lawmakers attempt to lift injunction by revising transparency bill to resemble legislation from Maine.
Express Scripts Sees Rapid Switching to Zocor
The success at switching patients to Zocor ahead of the availability of a generic demonstrates the success of PBMs in driving market share, CEO Paz says.
PCMA Challenges D.C.'s PBM "Transparency" Provision In Federal Court
The PBM association's arguments against Title II of D.C.'s "AccessRx Act of 2004" mirror those made in a similar case in Maine. PCMA contends that the law, which requires PBMs to disclose financial arrangements with drug manufacturers, is unconstitutional and preempted by ERISA.